Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study

BACKGROUND: Tumour necrosis factor inhibitor (TNFi) therapy has been available for rheumatoid arthritis (RA) patients for several decades but data on the long-term risk of malignancy associated with its use is limited. Our aims were to assess malignancy risk in a cohort of Australian RA patients rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Staples, Margaret P., March, Lyn, Hill, Catherine, Lassere, Marissa, Buchbinder, Rachelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390524/
https://www.ncbi.nlm.nih.gov/pubmed/30886989
http://dx.doi.org/10.1186/s41927-018-0050-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390524/
https://www.ncbi.nlm.nih.gov/pubmed/30886989
http://dx.doi.org/10.1186/s41927-018-0050-7

Ejemplares similares